tradingkey.logo

Myriad Genetics Inc

MYGN
6.550USD
-0.010-0.15%
Close 12/24, 13:00ETQuotes delayed by 15 min
609.80MMarket Cap
LossP/E TTM

Myriad Genetics Inc

6.550
-0.010-0.15%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Myriad Genetics Inc

Currency: USD Updated: 2025-12-23

Key Insights

Myriad Genetics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 92/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 8.06.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Myriad Genetics Inc's Score

Industry at a Glance

Industry Ranking
92 / 208
Overall Ranking
221 / 4568
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 13 analysts
Hold
Current Rating
8.064
Target Price
+14.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Myriad Genetics Inc Highlights

StrengthsRisks
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.47% year-on-year.
Overvalued
The company’s latest PE is -1.51, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 92.00M shares, decreasing 10.78% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 21.15K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.07.

Financial Health

Currency: USD Updated: 2025-12-23

The current financial score of Myriad Genetics Inc is 7.01, ranking 110/208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 205.70M, representing a year-over-year decrease of 3.56%, while its net profit experienced a year-over-year decrease of 23.98%.

Score

Industry at a Glance

Previous score
7.01
Change
0

Financials

7.74

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

5.80

Operational Efficiency

8.52

Growth Potential

5.83

Shareholder Returns

7.14

Myriad Genetics Inc's Company Valuation

Currency: USD Updated: 2025-12-23

The current valuation score of Myriad Genetics Inc is 7.90, ranking 56/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.51, which is -40.89% below the recent high of -0.89 and -1326.10% above the recent low of -21.52.

Score

Industry at a Glance

Previous score
7.90
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 92/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-23

The current earnings forecast score of Myriad Genetics Inc is 5.85, ranking 189/208 in the Healthcare Equipment & Supplies industry. The average price target for Myriad Genetics Inc is 8.00, with a high of 18.00 and a low of 3.50.

Score

Industry at a Glance

Previous score
5.85
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts
Hold
Current Rating
8.064
Target Price
+14.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

112
Total
6
Median
9
Average
Company name
Ratings
Analysts
Myriad Genetics Inc
MYGN
13
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-23

The current price momentum score of Myriad Genetics Inc is 5.29, ranking 181/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 7.59 and the support level at 6.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.01
Change
-0.72

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(4)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.128
Sell
RSI(14)
40.330
Neutral
STOCH(KDJ)(9,3,3)
11.720
Oversold
ATR(14)
0.290
High Vlolatility
CCI(14)
-127.630
Sell
Williams %R
94.565
Oversold
TRIX(12,20)
-0.193
Sell
StochRSI(14)
23.824
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
6.704
Sell
MA10
6.913
Sell
MA20
7.126
Sell
MA50
7.256
Sell
MA100
7.005
Sell
MA200
6.624
Sell

Institutional Confidence

Currency: USD Updated: 2025-12-23

The current institutional shareholding score of Myriad Genetics Inc is 10.00, ranking 1/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 98.69%, representing a quarter-over-quarter decrease of 8.90%. The largest institutional shareholder is The Vanguard, holding a total of 7.77M shares, representing 8.34% of shares outstanding, with 27.59% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
13.43M
-3.01%
The Vanguard Group, Inc.
Star Investors
9.15M
-13.83%
State Street Investment Management (US)
4.81M
-8.71%
Millennium Management LLC
4.92M
+21.01%
Glenview Capital Management, LLC
Star Investors
4.59M
+17.64%
D. E. Shaw & Co., L.P.
4.51M
+78.84%
Morgan Stanley & Co. LLC
3.37M
+140.14%
Geode Capital Management, L.L.C.
2.22M
-0.35%
Camber Capital Management LP
2.00M
-14.89%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-23

The current risk assessment score of Myriad Genetics Inc is 4.66, ranking 99/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.81. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.66
Change
0
Beta vs S&P 500 index
1.81
VaR
+5.07%
240-Day Maximum Drawdown
+74.37%
240-Day Volatility
+82.41%

Return

Best Daily Return
60 days
+7.14%
120 days
+46.51%
5 years
+46.51%
Worst Daily Return
60 days
-21.03%
120 days
-21.03%
5 years
-41.27%
Sharpe Ratio
60 days
-0.62
120 days
+0.75
5 years
-0.21

Risk Assessment

Maximum Drawdown
240 days
+74.37%
3 years
+86.57%
5 years
+89.53%
Return-to-Drawdown Ratio
240 days
-0.75
3 years
-0.25
5 years
-0.18
Skewness
240 days
+0.63
3 years
+0.66
5 years
+0.45

Volatility

Realised Volatility
240 days
+82.41%
5 years
+61.07%
Standardised True Range
240 days
+7.22%
5 years
+14.74%
Downside Risk-Adjusted Return
120 days
+148.30%
240 days
+148.30%
Maximum Daily Upside Volatility
60 days
+45.91%
Maximum Daily Downside Volatility
60 days
+54.23%

Liquidity

Average Turnover Rate
60 days
+1.93%
120 days
+2.10%
5 years
--
Turnover Deviation
20 days
+107.13%
60 days
+60.80%
120 days
+75.27%

Peer Comparison

Healthcare Equipment & Supplies
Myriad Genetics Inc
Myriad Genetics Inc
MYGN
6.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
Tactile Systems Technology Inc
TCMD
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
UFP Technologies Inc
UFP Technologies Inc
UFPT
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Myriad Genetics Inc?

The TradingKey Stock Score provides a comprehensive assessment of Myriad Genetics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Myriad Genetics Inc’s performance and outlook.

How do we generate the financial health score of Myriad Genetics Inc?

To generate the financial health score of Myriad Genetics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Myriad Genetics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Myriad Genetics Inc.

How do we generate the company valuation score of Myriad Genetics Inc?

To generate the company valuation score of Myriad Genetics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Myriad Genetics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Myriad Genetics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Myriad Genetics Inc.

How do we generate the earnings forecast score of Myriad Genetics Inc?

To calculate the earnings forecast score of Myriad Genetics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Myriad Genetics Inc’s future.

How do we generate the price momentum score of Myriad Genetics Inc?

When generating the price momentum score for Myriad Genetics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Myriad Genetics Inc’s prices. A higher score indicates a more stable short-term price trend for Myriad Genetics Inc.

How do we generate the institutional confidence score of Myriad Genetics Inc?

To generate the institutional confidence score of Myriad Genetics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Myriad Genetics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Myriad Genetics Inc.

How do we generate the risk management score of Myriad Genetics Inc?

To assess the risk management score of Myriad Genetics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Myriad Genetics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Myriad Genetics Inc.
KeyAI